Tianjin Tianyao Pharmaceuticals is an API manufacturer based in China. It holds 23 active US drug master files across a filed portfolio of 14 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 13 December 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3008256667 |
| Molecule | Regulators | Docs |
|---|---|---|
| Methylprednisolone | US FDA | 4 |
| Betamethasone | US FDA | 3 |
| Dexamethasone | US FDA | 3 |
| Prednisolone | SFDA (Saudi Arabia), US FDA | 3 |
| Prednisone | SFDA (Saudi Arabia), US FDA | 3 |
| Mometasone Furoate | US FDA | 2 |
| Budesonide | US FDA | 1 |
| Celecoxib | US FDA | 1 |
| Deflazacort | US FDA | 1 |
| Fluocinonide | US FDA | 1 |
| Fluticasone Propionate | US FDA | 1 |
| Hydrocortisone | US FDA | 1 |
| Spironolactone | US FDA | 1 |
| Triamcinolone | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| US FDA | None | 1 |
Choose your molecules and target markets. Tianjin Tianyao Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free